Agreement of Intraocular Pressure Measurement of Icare ic200 with Goldmann Applanation Tonometer in Adult Eyes with Normal Cornea.
Swathi Vallabh Badakere, Raghava Chary, Nikhil S Choudhari...
https://pubmed.ncbi.nlm.nih.gov/34030826/Actively Recruiting
Led by The University of Hong Kong · Updated on 2026-09-03
142
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the impact of home intra-ocular pressure IOP telemonitoring combined with smartphone-based intervention versus smartphone-based intervention alone in patients with newly diagnosed primary open-angle glaucoma POAG. This 30-month prospective, randomized clinical trial aims to compare IOP levels measured by Goldmann applanation tonometry GAT and rates of retinal nerve fiber layer RNFL thinning between these two management approaches. The study seeks to determine if home telemonitoring allows more precise IOP assessment to guide therapy and slow disease progression. Participants are randomly assigned to one of two management paradigms. Management Paradigm I involves using the iCare HOME rebound tonometer to self-measure IOP at home, with at least six measurements per week uploaded to a secure cloud system. Investigators review these data monthly to adjust treatment following a defined algorithm. Management Paradigm II includes standard care with topical prostaglandin analogue treatment guided by clinic-measured IOP and the same smartphone-based intervention without home telemonitoring. Both groups receive smartphone messages every 4 weeks about IOP control and medication adherence. During the 30-month study, participants attend clinic visits every 3 months for GAT IOP measurements, optical coherence tomography OCT imaging of the RNFL, and visual field testing. Researchers monitor changes in IOP, RNFL and ganglion cell inner plexiform layer thicknesses, and visual field progression. Safety is assessed by tracking adverse changes such as visual acuity loss or IOP spikes. Participants continue home IOP monitoring if assigned to Management Paradigm I until study completion, with ongoing adherence and treatment adjustments monitored via smartphone communication.
CONDITIONS
Impact of Home Intraocular Pressure Telemonitoring on Intraocular Pressure Control and Glaucoma Progression
C
Christopher Leung
A
Anita Yau
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The University of Hong Kong
Lead Sponsor
Icare Finland Oy
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 4 weeks
Participants perform 4 weeks of home intraocular pressure measurements to establish baseline levels.
Regular self-measurements at home
Duration - 30 months
Participants follow their assigned management paradigm: home IOP telemonitoring with smartphone support or standard care with smartphone support. Clinic visits occur every 3 months for eye pressure measurements, imaging, and vision tests. Treatment adjustments are made based on data collected.
Clinic visits every 3 months; home monitoring ongoing for assigned group
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Swathi Vallabh Badakere, Raghava Chary, Nikhil S Choudhari...
https://pubmed.ncbi.nlm.nih.gov/34030826/Boel Bengtsson, M Cristina Leske, Leslie Hyman...
https://pubmed.ncbi.nlm.nih.gov/17097736/Shunsuke Nakakura, Ryo Asaoka, Etsuko Terao...
https://pubmed.ncbi.nlm.nih.gov/34193284/Gail F Schwartz, Harry A Quigley
https://pubmed.ncbi.nlm.nih.gov/19038625/Yaniv Barkana, Sarah Anis, Jeffrey Liebmann...
https://pubmed.ncbi.nlm.nih.gov/16769832/Lucy I Mudie, Sophie LaBarre, Varshini Varadaraj...
https://pubmed.ncbi.nlm.nih.gov/27289178/Joseph Caprioli, Anne L Coleman
https://pubmed.ncbi.nlm.nih.gov/18082889/Seth R Flaxman, Rupert R A Bourne, Serge Resnikoff...
https://pubmed.ncbi.nlm.nih.gov/29032195/Karen L Margolis, Stephen E Asche, Anna R Bergdall...
https://pubmed.ncbi.nlm.nih.gov/23821088/John H K Liu, Xiaoyan Zhang, Daniel F Kripke...
https://pubmed.ncbi.nlm.nih.gov/12657596/The University of Hong Kong
Lead Sponsor
Icare Finland Oy
Collaborating Sponsor